On 4 June, 2021, Pharmaxis (ASX: PXS) hosted an investor briefing with CEO Gary Phillips to update investors on recent achievements and future plans, plus a Q&A with attendees.
Topics discussed in the briefing and question time included:
Pharmaxis is in a rare microcap air for a pharmaceutical research company that has a commercialised product at market with sales nearing profitability that can fund transformational cancer research. Addressing a substantial market opportunity through targeting of myelofibrosis where current treatment standards are limited, yet still sell upwards of USD $1 billion per year.
In May 2021, Emerald Financial published a research report on Pharmaxis which can be downloaded here.
- This company turns bananas into sustainable food packaging - September 17, 2021
- EMVision is pioneering the next generation of stroke diagnosis - September 16, 2021
- Encouraging data for Orthocell biotech in pursuit of next gen ACL knee reconstructions - September 15, 2021